R. Poon

Annals of Surgery · 2000–2015

A researcher in the Science corpus: 13 papers; trusts 0 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Whom R. Poon trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Strasberg

Who trusts R. Poon overall

1. Jordi Bruix1 , 2
2. F. Grin
3. J. Llovet
4. M. Sherman

Papers from R. Poon's perspective

Ordered by how strongly the researchers R. Poon trusts endorse each paper. Same corpus, a different order for every researcher.

1. Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
2. One thousand fifty-six hepatectomies without mortality in 8 years. (Archives of Surgery)
3. Improvement in Perioperative Outcome After Hepatic Resection: Analysis of 1,803 Consecutive Cases Over the Past Decade (Annals of Surgery)
4. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
5. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
6. Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years (Annals of Surgery)
7. The Brisbane 2000 terminology of liver anatomy and resections.
8. Diagnosis and treatment of hepatocellular carcinoma. (Gastroenterology)
9. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)
10. Presentation of multivariate data for clinical use: The Framingham Study risk score functions

Their papers

• Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. (2013) — 698 citations
• Clinical implications of circulating angiogenic factors in cancer patients. (2001) — 611 citations
• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010) — 1,052 citations
• Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. (2015) — 754 citations
• Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (2015) — 937 citations
• Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. (2014) — 659 citations
• Significance of CD90+ cancer stem cells in human liver cancer. (2008) — 1,228 citations
• Improving Perioperative Outcome Expands the Role of Hepatectomy in Management of Benign and Malignant Hepatobiliary Diseases: Analysis of 1222 Consecutive Patients From a Prospective Database (2004) — 711 citations
• Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (2002) — 848 citations
• Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (2002) — 2,596 citations
• Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years (2001) — 595 citations
• Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. (2000) — 865 citations
• Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma (2000) — 746 citations